KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Research & Development (2016 - 2025)

Historic Research & Development for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $2.5 billion.

  • Bristol Myers Squibb's Research & Development rose 648.69% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 billion, marking a year-over-year increase of 105.3%. This contributed to the annual value of $11.2 billion for FY2024, which is 2000.22% up from last year.
  • As of Q3 2025, Bristol Myers Squibb's Research & Development stood at $2.5 billion, which was up 648.69% from $2.6 billion recorded in Q2 2025.
  • Bristol Myers Squibb's 5-year Research & Development high stood at $3.2 billion for Q4 2024, and its period low was $2.2 billion during Q1 2021.
  • In the last 5 years, Bristol Myers Squibb's Research & Development had a median value of $2.5 billion in 2021 and averaged $2.5 billion.
  • Its Research & Development has fluctuated over the past 5 years, first tumbled by 1885.91% in 2022, then surged by 2877.32% in 2024.
  • Over the past 5 years, Bristol Myers Squibb's Research & Development (Quarter) stood at $2.5 billion in 2021, then fell by 0.32% to $2.5 billion in 2022, then decreased by 1.27% to $2.5 billion in 2023, then grew by 28.77% to $3.2 billion in 2024, then fell by 20.78% to $2.5 billion in 2025.
  • Its Research & Development stands at $2.5 billion for Q3 2025, versus $2.6 billion for Q2 2025 and $2.3 billion for Q1 2025.